Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label safety study of LY2189265 with oral antihyperglycemic monotherapy in type 2 diabetes
jRCT2080221664Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Dec 2011; status: recruiting.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221664.